NeuroPace (NPCE) said Tuesday that initial one-year results from its study evaluating the RNS system in idiopathic generalized epilepsy met the primary safety target but failed to achieve statistical significance for its primary effectiveness target in the full trial population.
The company said safety outcomes were consistent with earlier findings. However, the trial did not demonstrate a statistically significant improvement in the time to a second generalized tonic-clonic seizure across all participants, NeuroPace said.
A subgroup of patients with fewer seizures at the start of the study, representing the "majority of participants," indicated a statistically significant response, according to the company.
NeuroPace said it plans to submit the data to the US Food and Drug Administration and may seek approval for a narrower indication based on the subgroup findings.
The company reaffirmed its 2025 financial guidance. NeuroPace expects 2025 total revenue of $93 million to $97 million, the company said in its Q1 results earlier this month. Analysts polled by FactSet expect $94.8 million.
Shares of NeuroPace were down more than 15% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.